Matthew Zorn

Over the past few weeks, a cascade of federal moves has reshaped the conversation around psychedelic-assisted therapy in the United States. What was once a fringe issue is now drawing bipartisan attention—and, increasingly, institutional support. The clearest signal came from FDA Commissioner Dr....